Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 11Active not recruiting 5Terminated 4Recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4Thoracic 1Lymphoid 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 20Lung Neoplasms 6Small Cell Lung Carcinoma 4Ovarian Neoplasms 4Neoplasms 4Colorectal Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Breast Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Urothelial Cancer 1Urinary Bladder Diseases 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Testicular Neoplasms 1

Interventions

Carboplatin 44Paclitaxel 43liposomal doxorubicin 23Topotecan 19Gemcitabine 18pembrolizumab 17Cyclophosphamide 17Bevacizumab 16Cisplatin 12niraparib 9olaparib 8fludarabine 7Taxes 7Docetaxel 7aldesleukin 6Nivolumab 6Doxorubicin 61-dodecylpyridoxal 6oregovomab 5fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5rucaparib 4durvalumab 4avelumab 4Surgical Procedures, Operative 4Melphalan 4Ipilimumab 4Interleukin-2 4Etoposide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Ovarian Neoplasms × durvalumab × Clear all
NCT04019288 2025-06-11

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
12 enrolled 13 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03277482 2025-05-31

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Dana-Farber Cancer Institute

Phase 1 Terminated
16 enrolled
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT03323398 2024-07-31

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

ModernaTX, Inc.

Phase 1/2 Terminated
79 enrolled 18 charts
GynecologicLymphoid

Lymphoma, Ovarian Neoplasms, Recurrence

NCT02669914 2018-11-06

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

Washington University School of Medicine

Phase 2 Terminated
4 enrolled 12 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡